News by subject: TRI

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study (FuschiA study) currently being initiated, at the Fanconi Anemia...

Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO)...

Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the pivotal AUGMENT-101...

...

nRichDX® has launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development....

Weight loss doctor CIsar A. Lara, M.D., announces revolutionary treatment results in...

Calliditas Therapeutics AB ("Calliditas"), today announced the presentations of new biomarker and subgroup analyses from the Phase 3 NefIgArd study with Nefecon (TARPEYO® (budesonide) delayed release capsules/Kinpeygo®) in adults with Primary IgA...

Promontory Therapeutics Inc., a clinical stage biotechnology company advancing immunogenic small molecule approaches in oncology, has become the first...

AbbVie today...

Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce that data from an ongoing Phase II study (PNOC022, NCT05009992) of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine...

SciBase Holding AB ("SciBase") (STO:SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of chronic...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Sam Barone, Chief Medical Officer, will give a presentation on the clinical development of...

Ionis Pharmaceuticals, Inc. today announced that The Journal of the American Medical...

In some patients, infection with the pandemic virus SARS-CoV-2 can trigger a dangerous immune response in hardened fatty deposits (plaques) lining the heart's largest blood vessels, a new study shows....

Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International...

Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today the publication of the Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial, a prospective study...

CurePSP has awarded its latest Pathway and Pipeline Grants and Urso Student Fellowships, totaling over $422,000. Recipients of the grants are: Dr. Kurt Farrell, assistant professor at the Icahn School of Medicine at Mount Sinai; Dr. Blas Couto,...

The Association of Diversity in Clinical Trials (AOD) proudly announces its newest partners, Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research. This strategic collaboration aims to drive diversity and inclusion...

In the dynamic landscape of clinical trials, the efficient enrollment of the right participants stands as a pivotal goal. This webinar...

ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas...

SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, announced that a new peer-reviewed publication will be presented during the International Myeloma Society...

Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the...

ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart...

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting...

BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today...

Chemomab Therapeutics Ltd. , (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare...

Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA nephropathy           Submission to the CHMP for full approval is based on the full two-year...

IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company...

Ariceum Therapeutics (Ariceum), a private biotech...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the clinical results from a study performed together with the University Children's...

ScreenPoint Medical is showcasing global momentum for Transpara, the world's leading Breast artificial intelligence (AI) software, here at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, September 28-30, 2023 (Booth...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory...

Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with...

September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to  collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and...

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that it has completed its Series A3 financing round with an additional investment of $5...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Taiwan Food and Drug...

Mirati Therapeutics, Inc.® , a commercial stage research and development biotechnology company, today announced...

Oral Biolife, a biotechnology firm specializing in therapies for dental diseases, has announced the publication of a groundbreaking study in the journal ACS Applied Materials & Interfaces journal. The research highlights the efficacy of the company's...

A cellular signal essential to the development of the skeleton increases during aging to weaken bones, finds a new study in mice. ...

Scientists in Cambridge and Oxford are developing a new generation of rapid healthcare tests capable of detecting and characterising a wide range of diseases within minutes. The new, miniaturised tests are expected to enable the identification of up...

EnCompass Technologies, Inc., a privately held medical device company focused on protecting patients from brain injury during cardiovascular procedures, announced the US Food and Drug Administration (FDA) officially granted conditional...

Graves Gilbert, a multispecialty clinic comprised of more than 200 providers representing over 30 medical specialties in Bowling Green, Kentucky, and surrounding counties, is proud to announce a collaboration with Circuit Clinical, an integrated...

Omeza, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced that it has completed a $6.5 million offering and issuance of Series Seed Preferred Stock. The proceeds of this equity...

A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy,...

Nektar Therapeutics announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG").  The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in...

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present...

Compugen Ltd.  a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to...

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin treatments is excited to announce that a physician has been authorized to receive APEX-90 macrodose psilocybin drug product...